Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth J Kelly

Showing results (11-20 of 52) with videos related to

Pageof 6
Sort By:
Scientific Reports|May 13, 2022
Serum levels of anti-PF4 IgG after AZD1222 (ChAdOx1 nCoV-19) vaccinationTaylor S Cohen, Elizabeth J Kelly, Sven Nylander, et al.
Vaccine|June 4, 2023
One year safety and immunogenicity of AZD1222 (ChAdOx1 nCoV-19): Final analysis of a randomized, placebo-controlled phase 1/2 trial in JapanKensuke Ishikawa, Maria-Claudia Nascimento, Michiko Asano, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 6, 2017
Oncolytic VSV Primes Differential Responses to Immuno-oncology TherapyNicholas M Durham, Kathy Mulgrew, Kelly McGlinchey, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|October 24, 2021
Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trialMichiko Asano, Hiroshi Okada, Yohji Itoh, et al.
Frontiers in Immunology|October 30, 2023
Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protectionTyler Brady, Corinne Cayatte, Tiffany L Roe, et al.
Physiological Genomics|March 8, 2012
Genetically determined heterogeneity of lung disease in a mouse model of airway mucus obstructionAlessandra Livraghi-Butrico, Barbara R Grubb, Elizabeth J Kelly, et al.
Pediatrics|October 1, 2024
RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab DosingDeidre Wilkins, Ulrika Wählby Hamrén, Yue Chang, et al.
Clinical & Translational Immunology|May 2, 2022
Validation and performance of a multiplex serology assay to quantify antibody responses following SARS-CoV-2 infection or vaccinationDeidre Wilkins, Anastasia A Aksyuk, Alexey Ruzin, et al.
Frontiers in Immunology|June 3, 2024
Seasonal human coronavirus humoral responses in AZD1222 (ChaAdOx1 nCoV-19) COVID-19 vaccinated adults reveal limited cross-immunityAnn Marie Stanley, Anastasia A Aksyuk, Deidre Wilkins, et al.
Cell Reports. Medicine|January 7, 2023
AZD1222-induced nasal antibody responses are shaped by prior SARS-CoV-2 infection and correlate with virologic outcomes in breakthrough infectionAnastasia A Aksyuk, Himanshu Bansal, Deidre Wilkins, et al.
Pageof 6

Showing results (11-20 of 52) with videos related to

Sort By:
Pageof 6
Scientific Reports|May 13, 2022
Serum levels of anti-PF4 IgG after AZD1222 (ChAdOx1 nCoV-19) vaccinationTaylor S Cohen, Elizabeth J Kelly, Sven Nylander, et al.
Vaccine|June 4, 2023
One year safety and immunogenicity of AZD1222 (ChAdOx1 nCoV-19): Final analysis of a randomized, placebo-controlled phase 1/2 trial in JapanKensuke Ishikawa, Maria-Claudia Nascimento, Michiko Asano, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 6, 2017
Oncolytic VSV Primes Differential Responses to Immuno-oncology TherapyNicholas M Durham, Kathy Mulgrew, Kelly McGlinchey, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|October 24, 2021
Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trialMichiko Asano, Hiroshi Okada, Yohji Itoh, et al.
Frontiers in Immunology|October 30, 2023
Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protectionTyler Brady, Corinne Cayatte, Tiffany L Roe, et al.
Physiological Genomics|March 8, 2012
Genetically determined heterogeneity of lung disease in a mouse model of airway mucus obstructionAlessandra Livraghi-Butrico, Barbara R Grubb, Elizabeth J Kelly, et al.
Pediatrics|October 1, 2024
RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab DosingDeidre Wilkins, Ulrika Wählby Hamrén, Yue Chang, et al.
Clinical & Translational Immunology|May 2, 2022
Validation and performance of a multiplex serology assay to quantify antibody responses following SARS-CoV-2 infection or vaccinationDeidre Wilkins, Anastasia A Aksyuk, Alexey Ruzin, et al.
Frontiers in Immunology|June 3, 2024
Seasonal human coronavirus humoral responses in AZD1222 (ChaAdOx1 nCoV-19) COVID-19 vaccinated adults reveal limited cross-immunityAnn Marie Stanley, Anastasia A Aksyuk, Deidre Wilkins, et al.
Cell Reports. Medicine|January 7, 2023
AZD1222-induced nasal antibody responses are shaped by prior SARS-CoV-2 infection and correlate with virologic outcomes in breakthrough infectionAnastasia A Aksyuk, Himanshu Bansal, Deidre Wilkins, et al.
Pageof 6